文献速递妇科

澳大利亚晚期上皮性卵巢癌间隔减瘤术与初次减瘤术的围手术期结局:国家妇科肿瘤登记处(NGOR)研究

Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study.
PubMed 文献 · Gynecol Oncol · 2025-07-22

该研究基于澳大利亚国家妇科肿瘤登记处(NGOR)2017至2022年数据,纳入1084例III-IV期上皮性卵巢/输卵管/腹膜癌患者,比较初次减瘤术(PCS)与间隔减瘤术(ICS)的围手术期结局和总生存(OS)。PCS组470例(43%),ICS组614例(57%);ICS组术后并发症更少、满意减瘤率更高,但倾向性匹配后PCS组OS更长。

要点

  • PCS组470例(43%),ICS组614例(57%),ICS组术后并发症(Clavien Dindo III级及以上)更少。
  • ICS组满意减瘤(肉眼残留病灶<1 cm)率更高(p=0.047),两组完全减瘤无差异。
  • 中位OS为4.1年(IQR 3.9-4.4),倾向性匹配后PCS组OS长于ICS组(p<0.001)。

核心结论

  • 在III-IV期上皮性卵巢/输卵管/腹膜癌患者中,与PCS相比,ICS与更少的围手术期并发症和更高的满意减瘤率相关。
  • 然而,在该登记队列中PCS与改善的总生存相关。
  • 该结果与国际文献一致,研究使用国家临床质量登记数据报告了澳大利亚当前实践。

研究设计与样本

  • 澳大利亚国家妇科肿瘤登记处(NGOR)研究,纳入2017至2022年登记的III-IV期上皮性卵巢/输卵管/腹膜癌且接受减瘤术的所有女性(N=1084)。
  • 比较初次减瘤术(PCS)与间隔减瘤术(ICS),评估术后并发症(Clavien Dindo III级及以上)、满意和完全减瘤、总生存、术中并发症及乡村性、体能状态、年龄和社会经济地位对结局的影响。

主要发现

  • PCS组470例(43%),ICS组614例(57%)。
  • 术后并发症在PCS组较ICS组更常见(p=0.025和p=0.009)。
  • 满意减瘤(肉眼残留病灶<1 cm)在ICS组更常实现(p=0.047);两组完全减瘤无差异。
  • 中位OS为4.1年(IQR 3.9-4.4);倾向性匹配后PCS组生存长于ICS组(p<0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The National Gynae-Oncology Registry (NGOR) is an Australian Clinical Quality Registry (CQR). This study reports data on surgical outcomes in patients who underwent cytoreductive surgery for Stage III-IV epithelial Ovarian/Tubal/Peritoneal (OTP) cancer between 2017 and 2022. This study aims to understand rates of perioperative adverse events, complete and optimal cytoreduction, and factors that contribute to this in addition to comparing overall survival (OS) in those who undergo primary cytoreduction (PCS) versus interval cytoreduction (ICS). In doing so, this study aims to evaluate current Australian practice. METHOD: All women with Stage III-IV epithelial OTP cancer who underwent cytoreductive surgery between 2017 and 2022 registered with the NGOR were included (N = 1084). Outcomes included: rates of postoperative complications (Clavien Dindo Grade III+), PCS and ICS, complete and optimal cytoreduction, OS, intraoperative complications, and the effects of rurality, performance status, age and socioeconomic status on these outcomes. RESULTS: PCS was undertaken in 470 (43 %) patients and ICS in 614 (57 %) patients. Postoperative complications were more common in those who underwent PCS versus ICS (p = 0.025 and p = 0.009 respectively). Optimal cytoreduction (macroscopic residual disease <1 cm) was more commonly achieved at ICS (p = 0.047). No difference was observed between groups for complete cytoreduction. Median OS was 4.1 years [IQR 3.9-4.4] with those undergoing PCS surviving longer than those who undergo ICS after propensity matching (p < 0.001). CONCLUSION: ICS was associated with less perioperative morbidity, and increased rates of optimal cytoreduction when compared with PCS in patients with Stage III-IV epithelial OTP cancer. PCS was, however, associated with improved overall survival in this registry cohort. This is consistent with international literature and this study uses national CQR data to report on current Australian practice.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. McGauran M, Hyde S, Perera S, et al. Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study. Gynecol Oncol. 2025. PMID: 40700853. doi:10.1016/j.ygyno.2025.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。